Biotechnology

With two high-profile board appointments, Stellaromics signals its ambition to dominate the 3D spatial omics market with its advanced Pyxa™ platform.

A new partnership between GeminiBio and Tolemy Bio introduces aiMOS™, an AI-powered service designed to cut costs and boost consistency in cell therapy production.

With a new CEO and stunning clinical data, BOOST Pharma advances a potential game-changer for children with the rare genetic disorder Osteogenesis Imperfecta.

Aardvark Therapeutics is expanding its Phase 3 trial for a novel Prader-Willi Syndrome drug to include children as young as seven, targeting a key unmet need.

Ahead of its first Climate Week, Mumbai's food innovators and activists gather to debate a sustainable future, proving the fight for the planet begins on our plates.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

The advisory giant's acquisition of a Boston-based specialist signals a strategic push into the high-stakes, high-growth world of life sciences and biotech.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

A new partnership between South Korea's GCCL and Europe's Medicover MICS promises to streamline drug development by creating a seamless East-West axis.

Swiss pharma Santhera appoints Stifel as advisor, a strategic move to fuel the global rollout of its DMD drug AGAMREE amid a complex biotech funding market.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A Chinese biotech's novel nasal spray flu vaccine enters trials. Its unique design could finally make it safe for the elderly and expand global access.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.